Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01774071 · ClinicalTrials.gov registry record · Phase 1
Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01774071: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01774071 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01774071, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an antibody that works against STEAP1 - found on the surface of prostate cancer cells. Attached to the DFO-MSTP2109A is a radioactive material called 89ZR, which allows it to be imaged by a PET scanner. The results of this study may help researchers know whether 89Zr-DFO-MSTP2109A can be used as a diagnostic agent for finding prostate cancer that have STEAP1 on its surface with a PET scanner. The reason why identifying STEAP1 on prostate cancer cells is that new therapies are being developed to target STEAP1 prostate cancer cells.
Interventions
- DRUG 89Zr- DFO-MSTP2109A
- DRUG 89Zr DFO-MSTP2109A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-01 |
| Est. Completion | 2023-05-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01774071
The ClinicalTrials.gov registry entry for NCT01774071 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 89Zr- DFO-MSTP2109A is the first listed.
NCT01774071 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01774071 about?
NCT01774071 is a clinical study titled "Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer". The purpose of this study is to see if a new diagnostic research agent named 89Zr-DFO-MSTP2109A can show prostate cancer tumors on a PET scan; as well as see how long 89Zr-DFO-MSTP2109A lasts in the blood when given in small amounts. DFO-MSTP2109A is an antibody that works against STEAP1 - found on ...
What is the current status of trial NCT01774071?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-01. Estimated completion is 2023-05-02.
What interventions are being tested in trial NCT01774071?
The interventions under investigation include: 89Zr- DFO-MSTP2109A (DRUG), 89Zr DFO-MSTP2109A (DRUG).
Who is sponsoring clinical trial NCT01774071?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.